Image optimize LCP
  • Add description, images, menus and links to your mega menu

  • A column with no settings can be used as a spacer

  • Link to your collections, sales and even external links

  • Add up to five columns

  •  

     

     

     

    The Pratt Pouch is at an exciting point right now, on the verge of being introduced or expanded in a number of countries including Ecuador, Uganda, and Nigeria as the most prevalent contenders. With all the progress being made, we wanted to gather information of how the pouch is paired with the recommended ARV regimens, so we did some research on what drugs are recommended for babies born to HIV-positive mothers. Not only was this information usually buried in pages and pages of files, but it also varied widely across different sources. Some organizations provided regimens with specific measurements and timetables that depended on the regimen and serostatus of the mother, whereas other sources only had information as broad as “Nevirapine should be given to babies born to HIV-positive mothers.” With all the challenges we faced in comparing findings and determining reliable sources, we could not help but think what this means for a health clinic worker in Uganda or Ecuador. We are working with the marvels of modern technology, without language barriers, and with background understandings of reliable institutions. This just goes to show that access to the technologies for health are useless without access to information as well.

    Nevertheless, the most reoccurring and reliable information confirmed that babies born to HIV- positive mothers should be given Nevirapine (NVP) daily, either for 6 weeks or until one week after the end of breastfeeding. The essential aspect of this is that NVP treatment is started as soon as possible after birth. For mothers who give birth at home or away from a health clinic, the pouch makes this a realistic possibility. The Pratt Pouch simplifies the process of providing ARV medicine to babies. More than this, however, through this process we are consolidating the information needed not only to deliver medicine but to ensure that it is delivered effectively. This way, mothers do not have to worry about making frequent return trips to a health clinic, and health workers do not have to sort through hundreds of sources for ARV regimens while trying to get medicine delivered to a community.

    The pouch has gained global recognition from a number of sources, including WHO and USAID. Most recently, it won the Healthcare Innovation Award from the GlaxoSmithKline - Save the Children partnership. While awards and titles are encouraging, we really hope to use this momentum to implement the pouch in as many health care systems as possible. According to an estimate from USAID, Pratt Pouch could save 400,000 babies a year from HIV transmission. Regardless, every day 600 children are infected with HIV. We have the tools and technology to bring this number to zero. It is quite clear that this is not something that will happen overnight, but ensuring that the pouch is accessible for as many people as possible will make a huge impact in the future of prevention of mother-to-child transmission of HIV.

    Laisser un commentaire

    Les commentaires sont approuvés avant leur publication.


    Voir l'article entier

    The novel vital signs alert built into the CRADLE for eclampsia and shock detection
    The novel vital signs alert built into the CRADLE for eclampsia and shock detection

    novembre 26, 2024 2 lire la lecture

    The CRADLE Vital Signs Alert is an innovative semi-automatic device for midwifery and obstetrics.  The device takes blood pressure and heart rate and then calculates shock index, making the whole process semi-automatic. 
    Voir l'article entier
    NASG or TANN for postpartum hemorrhage CE-marked device
    Comment fonctionne réellement le NASG pour arrêter l’hémorragie et inverser le choc ?

    octobre 29, 2024 2 lire la lecture

    Le TANN (en espagnol) ou NASG est un dispositif de premiers secours obstétricaux. Il s'agit d'une grosse boule de mousse dense cousue solidement dans un rectangle de mousse, le tout conçu pour être bien ajusté autour de l'utérus et serré avec du velcro cousu.
    Voir l'article entier
    The bubble CPAP reducing neonatal mortality by 27 percent
    La CPAP à bulles réduit la mortalité néonatale de 27 %

    septembre 04, 2024 2 lire la lecture

    Expérience nigériane avec un projet pilote dans 7 hôpitaux utilisant le CPAP à bulles.
    Voir l'article entier